Endometrial cancer is the most common gynecological malignancies in high income countries. Despite advancements in its treatment, the quality of surgical care provided to these patients varies significantly, impacting clinical outcomes [[1], [2], [3]].

The European Society of Gynaecological Oncology (ESGO) proposed a set of evidence-based quality indicators (QIs) for the surgical management of endometrial carcinoma to ensure the delivery of standardized high- quality surgical care [[4], [5], [6], [7], [8]]. These indicators offer a structured approach to assess and enhance the quality of surgical interventions for endometrial cancer, aligning clinical practices with the highest standards of care.

These indicators serve as a critical benchmark for self-assessment, institutional quality assurance, and the establishment of a network of certified centers dedicated to excellence in gynecological oncology. The development of these QIs involved rigorous methodology, incorporating evidence-based practices and expert consensus to ensure relevance and applicability across diverse clinical settings [[9], [10], [11], [12], [13], [14]].

In France, the FrancoGYN research group has undertaken an extensive evaluation of these ESGO QIs by studying their applicability in a large cohort of endometrial cancer patients. This analysis not only highlights the current standards of surgical care within French institutions but also provides insights into the potential benefits of ESGO accreditation for improving the surgical outcomes for patients with endometrial cancer. In this context, our primary objective was to evaluate the real-world applicability and adherence to ESGO QIs across 13 French centers overs a 20-year period. Secondary objectives included assessing how practices evolved over time and identifying areas needing improvement.